Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
30 June 2021 | Story Dr Nitha Ramnath
Dr Charlene Marais, Prof Vladimir Azov and Prof Ulrich Hennecke

The Department of Chemistry at the University of the Free State (UFS) held a successful online International Symposium on Organic Chemistry on 15 June 2021. The symposium brought together scientists from several South African and foreign universities and created a virtual platform for a long-awaited discussion stalled by the COVID-19 pandemic. About 20 participants from universities in South Africa, Belgium, and Germany presented their lectures during the symposium. In addition, this symposium was directed at the postgraduate students in the Department of Chemistry at the UFS, allowing them to present their results to an international audience and to foster their engagement in scientific research.

For more than a year, the COVID-19 pandemic has prevented the common personal communication avenues for the researchers: face-to-face (F2F) conferences, symposia, and workshops. To bridge this gap, Prof Vladimir Azov and Dr Charlene Marais from the Department of Chemistry organised the online meeting for the researchers from the UFS and several other local and foreign universities, all working in the field of organic chemistry.

Online material from the International Symposium on Organic Chemistry is available at here

Collaborative project between the UFS and VUB towards the development of gel-based drug release systems

The symposium also served as a long-awaited inception meeting for the collaborative project between the Organic Chemistry group at the UFS and the Organic Chemistry (ORGC) group at the Vrije Universiteit Brussel (VUB). This project is jointly funded by the National Research Foundation (NRF) and FWO (Research Foundation – Flanders); it is aimed at the development of new peptide-based materials with properties controllable by precisely tuned interactions of unnatural amino acids included in the peptide sequence. Such peptides can, for example, be used as smart materials for precisely controllable drug release. The South African team members, directed by Prof Vladimir Azov, will specialise in the development of the new amino acid building blocks, whereas the VUB team, headed by Prof Ulrich Hennecke, will focus on peptide preparation and studies on their properties.

This kick-off meeting was initially planned as a F2F event in June 2020 but was delayed due to the COVID-19 travelling restrictions and finally migrated to a virtual space. This provided an opportunity to present the project proposals and to discuss the initial results in a much broader circle than would have been possible within the common F2F meeting framework.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept